相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient
Aude G. Chapuis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology
Mark J. Selby et al.
PLOS ONE (2016)
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Radiotherapy: Changing the Game in Immunotherapy
Sandra Demaria et al.
TRENDS IN CANCER (2016)
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis
Rony Dahan et al.
CANCER CELL (2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Scott N. Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Kathryn Baksh et al.
SEMINARS IN ONCOLOGY (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity
Valentina Rigo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Interleukin-21: a double-edged sword with therapeutic potential
Rosanne Spolski et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Interleukin-21 Enhances Rituximab Activity in a Cynomolgus Monkey Model of B Cell Depletion and in Mouse B Cell Lymphoma Models
Cecile M. Krejsa et al.
PLOS ONE (2013)
Synergistic effects of soluble PD-1 and IL-21 on antitumor immunity against H22 murine hepatocellular carcinoma
Xiu-Cheng Pan et al.
ONCOLOGY LETTERS (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Combination strategies to enhance antitumor ADCC
Holbrook E. Kohrt et al.
IMMUNOTHERAPY (2012)
Preclinical Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Interleukin-21 in Cynomolgus Macaques (Macaca fascicularis)
Kimberly S. Waggie et al.
INTERNATIONAL JOURNAL OF TOXICOLOGY (2012)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Novel Gamma-Chain Cytokines as Candidate Immune Modulators in Immune Therapies for Cancer
Natasha M. Fewkes et al.
CANCER JOURNAL (2010)
Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma
Charlotte Christie Petersen et al.
CYTOKINE (2010)
Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma
Mehmood H. Hashmi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins
Michael G. Dodds et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
Betty Li et al.
CLINICAL CANCER RESEARCH (2009)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
Karl S. Peggs et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Local IL-21 Promotes the Therapeutic Activity of Effector T cells by Decreasing Regulatory T Cells Within the Tumor Microenvironment
Seunghee Kim-Schulze et al.
MOLECULAR THERAPY (2009)
Angiostatic activity of the antitumor cytokine interleukin-21
Karolien Castermans et al.
BLOOD (2008)
Interleukin 21 enhances antibody-mediated tumor rejection
Mark J. Smyth et al.
CANCER RESEARCH (2008)
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
John A. Thompson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
IL-21-mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8(+) cytotoxic T lymphocytes
Yongqing Li et al.
BLOOD (2008)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors
Henrik Sondergaard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma
Ian D. Davis et al.
CLINICAL CANCER RESEARCH (2007)
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes
Ilaria Peluso et al.
JOURNAL OF IMMUNOLOGY (2007)
Interleukin-21 enhances NK cell activation in response to antibody-coated targets
Julie M. Roda et al.
JOURNAL OF IMMUNOLOGY (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:: Comparative evaluation of IL-2, IL-15, and IL-21
A Moroz et al.
JOURNAL OF IMMUNOLOGY (2004)
IL-21 in synergy with IL-15 or IL-18 enhances IFN-γ production in human NK and T cells
M Strengell et al.
JOURNAL OF IMMUNOLOGY (2003)
IL-21 UP-Regulates the expression of genes associated with innate immunity and Th1 response
M Strengeil et al.
JOURNAL OF IMMUNOLOGY (2002)
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function
J Parrish-Novak et al.
NATURE (2000)
Differentiating between memory and effector CD8 T cells by altered expression of cell surface O-glycans
LE Harrington et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
分享论文
